Showing 1771-1780 of 8580 results for "".
DERM2020 Exhibitor Reaction: Sam Widdicombe, Almirall
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-exhibitor-reaction-sam-widdicombe-almirall/19843/Sam Widdicombe of Almirall, a DERM2020 exhibitor, tells us what she thinks of the conference and has a few positive messages for her team.Scientifically Speaking: Botulinum Toxin Formulation and Testing
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-botulinum-toxin-formulation-and-testing/19832/Ever wonder about the differences in formulation and manufacture of botulinum neurotoxins? Curious about the trials that support approval? In this edition of Scientifically Speaking, Joel L. Cohen, MD gets the answers to these questions and more from Conor Gallagher, PhD, Head of Medical Affairs, ReNovel Treatments for Acne
https://practicaldermatology.com/topics/acne-rosacea/novel-treatments-for-acne/19761/Joshua Zeichner, MD discusses three new treatments now available in the acne treatment armamentarium. For patients with severe acne, a new low-dose isotretinoin in a micronized formulation allows for better absorption, even without food. Dr. Zeichner also discusses the benefits of a new topical retiCoding Challenges
https://practicaldermatology.com/topics/practice-management/coding-challenges/19741/Mark Kaufmann, MD discusses changing coding issues that will affect most dermatologists, including the need to get educated about new evaluation and management codes for 2021, modifier 25 issues, and global period codes being under pressure.Neuromarketing – what is it and how can it grow your dermatology practice?
https://practicaldermatology.com/topics/practice-management/neuromarketing-what-is-it-and-how-can-it-grow-your-dermatology-practice/19676/Marketing your dermatology practice isn’t all about algorithms and statistics. This Ekwa Marketing video will teach you how to boost your results by appealing to innate behavioral and psychological reactions of patients, with the scientifically proven principles of neuromarketing.Atopic Dermatitis: Rethinking the “Typical” Patient
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-rethinking-the-typical-patient/19666/It's possible to make generalities about the experience of atopic dermatitis, but it's increasingly clear that there is no "typical" patient. Zelma Chiesa Fuxench, MD discusses the latest findings on the signs and symptoms of AD and the populations affected.DermWireTV: Enbrel/AD Link, LGBTQ Health and Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-enbrelad-link-lgbtq-health-and-dermatology/19624/Signals in accumulated data for Enbrel seem to suggest that etanercept may have a protective effect against Alzheimer’s disease, the Washington Post reported earlier this month. The AAD position statement on Sexual and Gender Minority Health in Dermatology says that, “Dermatologists can and should cWhat ’s the Best Approach to AK Therapies? Ask an Expert
https://practicaldermatology.com/topics/skin-cancer-photoprotection/what-s-the-best-approach-to-ak-therapies-ask-an-expert/19622/Rather than consider AK a specific disease, Vishal A. Patel, MD, FAAD says it can be viewed as a marker of disease, which culminates in SCC. In this edition of Ask an Expert with Adam Friedman, MD, about his philosophy of treatment, including long-term maintenance.Tips to Increase Activity on your Dermatology Practice Facebook Page
https://practicaldermatology.com/topics/practice-management/tips-to-increase-activity-on-your-dermatology-prac/19602/Engaging with the Facebook users is essential to grow the business of your dermatology practice. In this Ekwa Marketing video, we share a few tips to help you expand your outreach on Facebook and sustain the necessary activity and interest on your page.Skin Cancer Awareness, Epiduo Data, Impoyz Launch
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-skin-cancer-awareness-epiduo-data-impoyz-launch/18307/Data shed light on patents' attitudes towards kids' sunblock and new findings emerge on melanoma risks. FDA accepts BLA for cemiplimab for advanced SCC and approves Novartis' Tafinlar in combination with Mekinist for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations